{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060756","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.520561+00:00","generated_at":"2026-06-15T00:48:10.387640+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cara Therapeutics Q1 2023 revenue $6.2M, net loss $26.7M; KORSUVA vial demand doubles","bullets":["Total revenue $6.2M (up from $4.8M YoY); net loss $26.7M ($0.49/sh) vs $27.7M ($0.52/sh) in Q1 2022.","KORSUVA injection net sales $5.7M; vial shipments to dialysis centers 45,720, more than doubling QoQ.","Cash, equivalents and securities $123.4M at March 31, 2023, down from $156.7M; cash runway into 2H24.","Oral difelikefalin: KIND 1 atopic dermatitis Part A readout on track for 4Q23; KICK CKD topline 2H24; KOURAGE NP Part A 2H24.","Kapruvia launched in four European countries; Japan PMDA decision expected 2H23."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060756","json":"https://secwatch.observer/filing/0001104659-23-060756.json","markdown":"https://secwatch.observer/filing/0001104659-23-060756.md","text":"https://secwatch.observer/filing/0001104659-23-060756.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/0001104659-23-060756-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/tm2315680d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:48:10.387640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40563166ece99d7366b908c419f217fe9305b06f","claim":"Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $6.2 million, net income $26.7 million, EPS $(0.49) per basic and diluted share.","evidence_excerpt":"For the first quarter of 2023, net loss was $26.7 million, or $(0.49) per basic and diluted share, compared to net loss of $27.7 million, or ($0.52) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.2 million and $4.8 million for the three months ended March 31, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465923060756/0001104659-23-060756-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$6.2 million"},{"label":"Net income","value":"$26.7 million"},{"label":"EPS","value":"$(0.49) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}